Moreover, HULC can function as a ceRNA for miR-200a to modulate MYC and Bcl-2 expression in CML cells; however, whether HULC is a new target for CML therapy needs still to be validated in particular using animal studies. The gene discussed is MYC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.